8-K: Verastem Halts RAMP 203 Lung Cancer Trial, Shifts Focus

Verastem Oncology announced the discontinuation of its RAMP 203 clinical trial for advanced KRAS G12C-mutated NSCLC to prioritize other promising programs.

Summary

• Verastem, Inc. is discontinuing the RAMP 203 Phase 1/2 clinical trial for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC).
• The decision was made after evaluating interim data and reflects the evolving treatment landscape for KRAS G12C inhibitors and strategic prioritization of programs with greater potential impact.
• Resources will be refocused on the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors.
• No further enrollment in RAMP 203 will occur, but currently enrolled patients may continue treatment per investigator discretion.
• RAMP 203 evaluated avutometinib and LUMAKRAS (sotorasib) in a doublet combination and also with defactinib as a triplet combination.
• As of November 26, 2025, the data cutoff, 66 patients were treated at the recommended Phase 2 dose and were evaluable for efficacy.
• For the doublet combination, 30 G12C-inhibitor treatment-naive patients achieved an overall response rate (ORR) of 40% (12/30) and a median progression-free survival (PFS) of 11.1 months.
• In the previously G12C-inhibitor treated group for the doublet combination, 21 patients achieved an ORR of 9.5% (2/21) and a median PFS of 3.7 months.
• Among six G12C-inhibitor treatment-naive patients in the triple combination, four were evaluable for efficacy and achieved an ORR of 50% (2/4).
• Among 12 patients on the triplet combination who were previously treated with a KRAS G12C inhibitor, 11 were efficacy evaluable and four (36%) showed greater than 30% tumor reduction, with seven still ongoing.
• Median PFS could not be determined in the triplet treatment-naive combination cohort, while those previously treated with a G12C inhibitor in the triplet combination showed a median PFS of 3.6 months.
• Across the doublet and triplet combinations evaluated, no dose-limiting toxicities were observed, and treatment-related adverse events were generally manageable, with nausea (56.8%), diarrhea (52.7%), and fatigue (45.9%) being the most common.

Sentiment

Score: 3

Explanation: The discontinuation of a clinical trial is a significant negative event, indicating that the drug candidate did not meet competitive efficacy benchmarks. While the company is pivoting to other programs with promising data (VS-7375), the immediate impact of a trial halt is generally unfavorable for investor sentiment.

Positives

• The company is strategically prioritizing VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, which demonstrated a 69% response rate (11 of 16, both confirmed and unconfirmed) in advanced KRAS G12D NSCLC.
• RAMP 203 provided important insights into treatment strategies and demonstrated proof-of-concept for avutometinib plus defactinib combined with a G12C inhibitor.
• No dose-limiting toxicities were observed across the RAMP 203 doublet and triplet combinations, and treatment-related adverse events were generally manageable.
• Verastem has an FDA-approved product, AVMAPKI FAKZYNJA CO-PACK, for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), approved on May 8, 2025.
• The company is continuing other clinical trials, including RAMP 301 (Phase 3 for LGSOC) and RAMP 205 (Phase 2 for advanced pancreatic cancer).

Negatives

• Discontinuation of the RAMP 203 Phase 1/2 clinical trial for advanced KRAS G12C-mutated non-small cell lung cancer.
• The decision reflects the evolving treatment landscape for KRAS G12C inhibitors, with next-generation inhibitors establishing a new benchmark with higher response rates, making RAMP 203 less competitive.
• The overall response rate (ORR) of 9.5% and median progression-free survival (PFS) of 3.7 months in previously G12C-inhibitor treated patients for the doublet combination in RAMP 203 was relatively low.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
• Applicable risks and uncertainties include the company's ability to successfully complete clinical development programs and any subsequent commercialization of the assets being developed.
• The company may not achieve the plans, intentions, or expectations disclosed in its forward-looking statements.
• The business is subject to substantial risks and uncertainties, including those identified under the heading 'Risk Factors' as detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company plans to strategically prioritize and focus resources on the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for advanced NSCLC and other solid tumors, given its promising 69% response rate. Additionally, Verastem will continue the RAMP 205 clinical trial for advanced pancreatic cancer and the RAMP 301 confirmatory trial for recurrent low-grade serous ovarian cancer (LGSOC). The company is also assessing opportunities to share the RAMP 203 data in the future.

Management Comments

• "While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates. Accordingly, we are prioritizing our clinical development of VS-7375, a potentially best-in-class oral KRAS G12D (ON/OFF) inhibitor, that demonstrated a 69% response rate (11 of 16, both confirmed and unconfirmed) in advanced KRAS G12D NSCLC and has the potential to help more patients with its differentiated approach in multiple solid tumors; and the RAMP 205 clinical trial evaluating avutometinib plus defactinib in combination with chemotherapy in first line metastatic pancreatic cancer." John Hayslip, Chief Medical Officer.
• "We sincerely appreciate and thank the investigators, patients, and families who participated in this program as these clinical outcomes will contribute to the development of novel therapies urgently needed for this challenging cancer." John Hayslip, Chief Medical Officer.

Industry Context

The decision to discontinue RAMP 203 reflects the rapidly evolving and competitive treatment landscape for KRAS G12C inhibitors. Next-generation inhibitors are setting higher benchmarks for response rates, necessitating a strategic shift for companies like Verastem to focus on programs with greater potential, such as their KRAS G12D inhibitor VS-7375, which targets a different KRAS mutation and has shown strong early efficacy. This strategic pivot is crucial for maintaining competitiveness in the oncology space.

Comparison to Industry Standards

• The RAMP 203 trial's overall response rate (ORR) of 40% in G12C-inhibitor treatment-naive patients for the doublet combination, and 9.5% in previously treated patients, is being compared unfavorably to "next generation G12C inhibitors" which are establishing a "new benchmark with higher response rates."
• Verastem's VS-7375, a KRAS G12D inhibitor, demonstrated a 69% response rate (11 of 16) in advanced KRAS G12D NSCLC, which is presented as a potentially "best-in-class" result and a key reason for strategic prioritization.

Stakeholder Impact

• Shareholders: Potential negative impact due to the discontinuation of a clinical trial, which can lead to a decrease in share price. However, the strategic pivot to more promising assets might mitigate long-term concerns.
• Patients: Patients currently enrolled in RAMP 203 have the option to continue treatment, but no new patients will be enrolled. Patients with KRAS G12C-mutated NSCLC lose a potential treatment option from Verastem's pipeline, though the company is focusing on other cancer types and mutations.
• Investigators: The trial discontinuation impacts ongoing research and resource allocation for participating investigators.
• Employees: The strategic shift may lead to reallocation of internal resources and personnel.

Next Steps

• Focus resources on clinical development of VS-7375 in advanced NSCLC and other solid tumors.
• Continue the RAMP 205 clinical trial evaluating avutometinib plus defactinib with chemotherapy in first-line metastatic pancreatic cancer.
• Continue the RAMP 301 Phase 3 confirmatory trial evaluating avutometinib and defactinib for recurrent low-grade serous ovarian cancer (LGSOC).
• Assess opportunities to share the RAMP 203 data in the future.

Key Dates

Recommendation

The discontinuation of a clinical trial is a negative development, reflecting that the drug candidate did not meet competitive efficacy benchmarks in an evolving landscape. While the company is pivoting to other promising assets like VS-7375 with strong early data and has an existing FDA-approved product, the immediate impact of a trial halt often leads to downward pressure on the stock. A "hold" recommendation acknowledges the negative news but also considers the strategic pivot and the potential of other pipeline assets, suggesting investors await further data from the prioritized programs before making a definitive buy or sell decision.

Keywords

Verastem, VSTM, RAMP 203, KRAS G12C, NSCLC, non-small cell lung cancer, clinical trial, discontinuation, avutometinib, LUMAKRAS, sotorasib, defactinib, VS-7375, KRAS G12D, oncology, biopharmaceutical, drug development, cancer therapy, MEK inhibitor, FAK inhibitor, RAF inhibitor, RAMP 205, RAMP 301, LGSOC, ovarian cancer, pancreatic cancer